Pentaaza Macrocyclic Complexes with Axial Ligands for Oral Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transition metal pentaaza 15-membered macrocyclic ring complexes exhibit limited oral bioavailability, with aqueous solutions providing less than 5% absorption and oil-based formulations offering insufficient bioavailability due to ionization and water solubility issues, hindering effective drug uptake across the intestinal barrier.
Innovation Solution
Development of transition metal complexes with pentaaza 15-membered macrocyclic rings and axial ligands, such as —OC(O)X1, that maintain a neutral form in the body, allowing for high systemic drug levels through oral and other administration routes, enhancing absorption and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If aqueous solutions of transition metal pentaaza macrocyclic ring complexes are used for oral administration, then the complexes can be administered orally, but oral bioavailability is less than 5% due to ionization and water solubility issues
Solution Approach 1:
The patent modifies the axial ligands of the transition metal complexes by introducing lipophilic substituents (such as fluorinated alkyl groups, aromatic rings, and hydrocarbon chains) to change the overall lipophilicity parameter of the complex. This parameter change enables the complex to maintain adequate water solubility for administration while achieving sufficient lipophilicity for intestinal membrane permeation, thereby resolving the contradiction between oral administration capability and oral bioavailability.
Solution Approach 2:
The patent creates composite molecular structures by combining the hydrophilic pentaaza macrocyclic ring complex core with lipophilic axial ligand substituents. This composite structure allows the molecule to possess both hydrophilic and lipophilic characteristics simultaneously, enabling it to dissolve in aqueous gastrointestinal fluids while also permeating the lipophilic intestinal barrier, thus resolving the bioavailability contradiction.
2Stability of the object's composition
If oil-based formulations are used to improve lipophilicity and absorption, then lipophilicity increases, but water solubility decreases leading to insufficient bioavailability
Solution Approach 1:
The patent carefully balances the lipophilicity parameter by selecting axial ligands with specific hydrocarbon chain lengths and aromatic substituents. The lipophilicity is increased enough to enable intestinal permeation but not so much that aqueous solubility is completely lost. This optimized parameter balance allows the complex to achieve sufficient bioavailability without requiring oil-based formulations.
Solution Approach 2:
The patent introduces lipophilic character locally through the axial ligand substituents while maintaining the overall hydrophilic nature of the complex core. This localized modification allows specific regions of the molecule to interact with lipophilic membranes while other regions maintain water solubility, resolving the contradiction between lipophilicity and water solubility.
3Reliability
If axial ligands are modified to enhance intestinal permeability, then oral bioavailability improves, but stability in various solvent systems may be compromised
Solution Approach 1:
The patent modifies axial ligand parameters such as substituent type, chain length, and aromaticity to optimize the balance between intestinal permeability and solvent stability. Specific fluorinated alkyl groups and aromatic substituents are selected because they provide both lipophilicity for permeation and chemical stability in physiological and formulation solvents, thus resolving the contradiction between improved bioavailability and maintained stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes achieve significant oral bioavailability and improved intestinal permeability, maintaining therapeutic efficacy while offering versatility in administration routes, including oral dosing, and stability in various solvent systems.
Implementation Method 1
the five nitrogens contained in the macrocyclic ring each form a coordinate covalent bond with the manganese (or other transition metal coordinated by the macrocycle) at the center of the molecule
Data Source
AI summary
Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X1.each of the two axial ligands has the formula —OC(═O)X1 wherein each X1 is independently substituted or unsubstituted phenyl or —C(—X2)(—X3)(—X4);each X2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl;each X3 is independently hydrogen, hydroxyl, alkyl, amino, —X5C(═O)R13 where X5 is NH or O, and R13 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or —OR14, where R14 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or together with X4 is (═O); andeach X4 is independenly hydrogen or together with X3 is (═O).